A selective inhibitor of intestinal ACAT, EAB309 suppresses both intestinal and hepatic cholesterol output and stimulates chylomicron removal.
The effect of a novel inhibitor of acylcoenzyme A:cholesterol acyltransferase (EC 2.3.1.26, ACAT), EAB309 (EAB) on plasma lipid metabolism was studied in cholesterol-fed rats. Orally administered EAB was not detected in the portal vein or the liver but distributed exclusively in the intestine, suggesting that this agent selectively inhibits intestinal ACAT. The rats were fed with either a cholesterol-diet or a cholesterol-diet containing 0.005% EAB (w/w) ad. libium for three weeks. ACAT activity in intestinal microsomes was significantly inhibited in EAB-treated rats. Hepatic ACAT activity was also decreased in EAB-treated rats, however, this was attenuated by the addition of excess cholesterol to the liver microsome, indicating that substrate availability is tightly associated with this enzyme's activity and the inhibition of hepatic ACAT by EAB is not direct. Incorporation of [3H]-cholesterol to cholesteryl ester (CE) in mesenteric lymph were markedly suppressed by EAB treatment. Chylomicrons (CMs) were doubly labeled with [3H]-vitamin A and [14C]-triglyceride (TG) in EAB-treated or non-treated rats and injected into normal chow-fed rats. The CMs from EAB-treated rats were cleared faster from the plasma and taken up more by the liver compared with the CMs from non-treated rats. The content of CE in newly secreted VLDL was remarkably decreased by EAB treatment without affecting TG output. These results demonstrate that EAB, a novel inhibitor of intestinal ACAT, significantly suppresses both intestinal and hepatic CE output and stimulates CM removal. This suggests that the inhibition of intestinal ACAT can subsequently suppress hepatic ACAT by decreased CE delivery from the intestine to the liver.
Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan.
Y
Y
Umeda
T
T
Hirano
Y
Y
Kako
K
K
Kamagata
K
K
Okuyama
K
K
Suzuki
D000818:Animals; D002784:Cholesterol / Q000008:administration & dosage / Q000096:biosynthesis / Q000097:blood*; D002914:Chylomicrons / Q000187:drug effects / Q000378:metabolism*; D004149:Dioxoles / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D007413:Intestinal Mucosa / Q000378:metabolism*; D007422:Intestines / Q000187:drug effects*; D008079:Lipoproteins, VLDL / Q000096:biosynthesis; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism*; D008198:Lymph Nodes / Q000378:metabolism; D008297:Male; D010671:Phenylurea Compounds / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D002785:Sterol O-Acyltransferase / Q000037:antagonists & inhibitors*; D014280:Triglycerides / Q000096:biosynthesis / Q000097:blood
D002914:Chylomicrons; D004149:Dioxoles; C087390:EAB 309; D004791:Enzyme Inhibitors; D008079:Lipoproteins, VLDL; D010671:Phenylurea Compounds; D014280:Triglycerides; D002784:Cholesterol; D002785:Sterol O-Acyltransferase